APASL Consensus Statements and Management Algorithms for Hepatitis C Virus Infection

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2015 Jul 24

PMID 26201405

Citations 85

Authors

Masao Omata

Tatsuo Kanda

Ming-Lung Yu

Osamu Yokosuka

Seng-Gee Lim

Wasim Jafri

Ryosuke Tateishi

Saeed S Hamid

Wan-Long Chuang

Anuchit Chutaputti

Lai Wei

Jose Sollano

Shiv Kumar Sarin

Jia-Horng Kao

Geoffrey W McCaughan

Affiliations

Soon will be listed here.

Abstract

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the "APASL Consensus Statements and Management Algorithms for Hepatitis C Virus Infection" in December, 2010, in order to revise "Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection (J Gastroenterol Hepatol 22:615-633, 2007)". The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Makuhari, Chiba, Japan on 19 December 2010. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations are presented in this review.

Citing Articles

Trends in sexually transmitted and blood-borne infections in China from 2005 to 2021: a joinpoint regression model.

Wang S, Chen J, Li Y, Zhang B, Li X, Han Y BMC Infect Dis. 2023; 23(1):741.

PMID: 37904156 PMC: 10614345. DOI: 10.1186/s12879-023-08733-8.

Outcome of hepatitis C patients in a community with predominant genotype 3 with standard-of-care treatment before and after advent of direct-acting antivirals: A retrospective-cum-prospective study.

Kadla S, Dar M, Shah N, Khan B, Shah A, Pathania R Indian J Pharmacol. 2020; 52(5):372-377.

PMID: 33283768 PMC: 8025768. DOI: 10.4103/ijp.IJP_516_18.

Association of Genetic Polymorphisms With Hepatitis C Virus-related Liver Cirrhosis in Japan.

Kamimura S, Tamura A, Ishii T, Kanda T, Moriyama M In Vivo. 2020; 34(6):3309-3313.

PMID: 33144438 PMC: 7811607. DOI: 10.21873/invivo.12169.

Are direct-acting antivirals against hepatitis C virus infection not associated with the recurrence of hepatocellular carcinoma?.

Ogawa M, Kanda T, Moriyama M Hepatobiliary Surg Nutr. 2019; 8(4):423-425.

PMID: 31489321 PMC: 6700000. DOI: 10.21037/hbsn.2019.03.19.

New treatments for HCV: Perspective from Asia.

Yu M, Chuang W Clin Liver Dis (Hoboken). 2019; 5(1):17-21.

PMID: 31312438 PMC: 6490446. DOI: 10.1002/cld.442.

References

Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O . Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000; 132(7):517-24. DOI: 10.7326/0003-4819-132-7-200004040-00002. View

. A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis. 2005; 192(11):1872-9. DOI: 10.1086/497695. View

Shiffman M, Suter F, Bacon B, Nelson D, Harley H, Sola R . Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357(2):124-34. DOI: 10.1056/NEJMoa066403. View

Vento S, Cainelli F, Cesario F . Infections and thalassaemia. Lancet Infect Dis. 2006; 6(4):226-33. DOI: 10.1016/S1473-3099(06)70437-6. View

Mangia A, Thompson A, Santoro R, Piazzolla V, Tillmann H, Patel K . An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010; 139(3):821-7, 827.e1. DOI: 10.1053/j.gastro.2010.05.079. View

Goodman Z, Makhlouf H, Liu L, Balistreri W, Gonzalez-Peralta R, Haber B . Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology. 2008; 47(3):836-43. PMC: 3755275. DOI: 10.1002/hep.22094. View

Potthoff A, Berg T, Wedemeyer H . Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol. 2009; 44(12):1487-90. DOI: 10.3109/00365520903329585. View

Ryder S, Irving W, Jones D, Neal K, Underwood J . Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004; 53(3):451-5. PMC: 1773967. DOI: 10.1136/gut.2003.021691. View

Chutaputti A . Adverse effects and other safety aspects of the hepatitis C antivirals. J Gastroenterol Hepatol. 2000; 15 Suppl:E156-63. DOI: 10.1046/j.1440-1746.2000.02114.x. View

10.

Martinot-Peignoux M, Stern C, Maylin S, Ripault M, Boyer N, Leclere L . Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010; 51(4):1122-6. DOI: 10.1002/hep.23444. View

11.

Tohme R, Holmberg S . Is sexual contact a major mode of hepatitis C virus transmission?. Hepatology. 2010; 52(4):1497-505. DOI: 10.1002/hep.23808. View

12.

Yeh M, Hung C, Huang J, Liu C, Lee C, Dai C . Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One. 2011; 6(6):e20752. PMC: 3113900. DOI: 10.1371/journal.pone.0020752. View

13.

Liu C, Chuang W, Lee C, Yu M, Lu S, Wu S . Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2008; 136(2):496-504.e3. DOI: 10.1053/j.gastro.2008.10.049. View

14.

Chevaliez S, Pawlotsky J . Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clin Liver Dis. 2005; 9(3):371-82, v. DOI: 10.1016/j.cld.2005.05.009. View

15.

Buti M, Lurie Y, Zakharova N, Blokhina N, Horban A, Teuber G . Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010; 52(4):1201-7. DOI: 10.1002/hep.23816. View

16.

Laperche S, Elghouzzi M, Morel P, Asso-Bonnet M, Le Marrec N, Girault A . Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing?. Transfusion. 2005; 45(12):1965-72. DOI: 10.1111/j.1537-2995.2005.00648.x. View

17.

Kweon S, Shin M, Song H, Jeon D, Choi J . Seroprevalence and risk factors for hepatitis C virus infection among female commercial sex workers in South Korea who are not intravenous drug users. Am J Trop Med Hyg. 2006; 74(6):1117-21. View

18.

. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001; 50(RR-5):1-43. View

19.

Verbeeck J, Stanley M, Shieh J, Celis L, Huyck E, Wollants E . Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol. 2008; 46(6):1901-6. PMC: 2446848. DOI: 10.1128/JCM.02390-07. View

20.

Mangia A, Santoro R, Minerva N, Ricci G, Carretta V, Persico M . Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 352(25):2609-17. DOI: 10.1056/NEJMoa042608. View